Superluminal Medicines Raises $60 Million to Advance Selective MC4R Obesity Drug into the Clinic

Superluminal Medicines has raised $60 million in an oversubscribed Series B financing to advance its lead selective MC4R agonist into clinical development for rare genetic forms of obesity and hypothalamic obesity. The company expects to begin a Phase 1 trial by the end of 2026, marking its transition from discovery-stage research toward human testing.

Targeting a Validated Obesity Pathway

The lead program targets the melanocortin-4 receptor (MC4R), a clinically validated pathway that regulates appetite and energy homeostasis. MC4R has particular relevance in rare obesity disorders, including Bardet-Biedl syndrome (BBS) and hypothalamic obesity, where disrupted signaling can contribute to severe abnormalities in appetite and energy balance.

Superluminal is developing a selective, biased MC4R agonist rather than broadly activating the receptor. The approach is intended to favor signaling associated with the desired therapeutic response while limiting unwanted effects. In preclinical studies, the candidate showed high selectivity and what the company described as a favorable safety profile. Those findings, however, have not been established in humans.

Phase 1 Will Test the Approach in Humans

The upcoming Phase 1 study will provide the first clinical assessment of the candidate’s safety and tolerability. The source does not yet provide details on planned enrollment, dosing cohorts, clinical endpoints, or the specific genetic obesity populations that will be included.

That early clinical readout will be important because the program’s central scientific premise remains untested in people. A successful transition from preclinical models into human development will help determine whether selective MC4R signaling can deliver sufficient therapeutic activity without compromising tolerability.

The company also sees potential applications beyond its initial development program. Prader-Willi syndrome represents a possible future rare-disease indication, while broader obesity could eventually be explored in combination with GLP-1 therapies. These remain future development possibilities rather than established clinical uses.

AI and Structural Biology Drive Discovery Platform

The financing will also support Superluminal’s broader drug-discovery platform, which combines artificial intelligence and machine learning with structural biology and protein dynamics. The company focuses initially on G protein-coupled receptors (GPCRs), a structurally complex class of drug targets.

Its platform incorporates Agentic Cryo-EM, GPCR-focused co-folding models, de novo small-molecule design across three-dimensional binding-pocket conformations, predictive ADME and toxicology models, and GPCR biophysics. Superluminal is also continuing a collaboration with Eli Lilly to discover small-molecule therapies against undisclosed GPCR targets in cardiometabolic disease and obesity.

$60 Million Financing Sets Up the Next Milestone

BVF Partners led the Series B, with participation from Deep Track Capital and Perceptive Advisors and existing investors including RA Capital Management, Insight Partners, NVIDIA, Catalio Capital Management, Eli Lilly and Company, Cooley, and Gaingels.

The company plans to use the capital to initiate Phase 1 development by the end of 2026, advance additional pipeline programs, and expand its GPCR discovery platform. The immediate priority remains establishing whether the selective MC4R strategy is safe and tolerable in humans and whether its preclinical rationale can translate into a clinically meaningful treatment for difficult-to-treat forms of obesity.

 Reference

Superluminal-Series-B_FINAL-2-1.pdf